These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37949414)

  • 1. The spatiotemporal journey of nanomedicines in solid tumors on their therapeutic efficacy.
    Qin M; Xia H; Xu W; Chen B; Wang Y
    Adv Drug Deliv Rev; 2023 Dec; 203():115137. PubMed ID: 37949414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.
    Durymanov MO; Rosenkranz AA; Sobolev AS
    Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical modeling of the heterogeneous distributions of nanomedicines in solid tumors.
    He H; Liu C; Liu Y; Liu X; Wu Y; Fan J; Zhao L; Cao Y
    Eur J Pharm Biopharm; 2019 Sep; 142():153-164. PubMed ID: 31226367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulating tumor mechanics with nanomedicine for cancer therapy.
    Zhao Q; Chen J; Zhang Z; Xiao C; Zeng H; Xu C; Yang X; Li Z
    Biomater Sci; 2023 Jun; 11(13):4471-4489. PubMed ID: 37221958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of biophysical properties of tumor extracellular matrix on intratumoral fate of nanoparticles: Implications on the design of nanomedicine.
    Tian Y; Cheng T; Sun F; Zhou Y; Yuan C; Guo Z; Wang Z
    Adv Colloid Interface Sci; 2024 Apr; 326():103124. PubMed ID: 38461766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
    van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
    Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.
    Yang J; Wang X; Wang B; Park K; Wooley K; Zhang S
    Adv Drug Deliv Rev; 2022 Nov; 190():114525. PubMed ID: 36100142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies of engineering nanomedicines for tumor retention.
    Qian X; Xu X; Wu Y; Wang J; Li J; Chen S; Wen J; Li Y; Zhang Z
    J Control Release; 2022 Jun; 346():193-211. PubMed ID: 35447297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
    Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
    Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing Tumor Penetration of Nanomedicines.
    Sun Q; Ojha T; Kiessling F; Lammers T; Shi Y
    Biomacromolecules; 2017 May; 18(5):1449-1459. PubMed ID: 28328191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current understandings and clinical translation of nanomedicines for breast cancer therapy.
    Jiang Y; Jiang Z; Wang M; Ma L
    Adv Drug Deliv Rev; 2022 Jan; 180():114034. PubMed ID: 34736986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization.
    Sun Q; Zhou Z; Qiu N; Shen Y
    Adv Mater; 2017 Apr; 29(14):. PubMed ID: 28234430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design considerations for nanotherapeutics in oncology.
    Stylianopoulos T; Jain RK
    Nanomedicine; 2015 Nov; 11(8):1893-907. PubMed ID: 26282377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
    Lakshmanan VK
    Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boosting antitumor efficacy of nanoparticles by modulating tumor mechanical microenvironment.
    Zhang X; Zhang X; Yong T; Gan L; Yang X
    EBioMedicine; 2024 Jul; 105():105200. PubMed ID: 38876044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines.
    Qin SY; Zhang AQ; Zhang XZ
    Small; 2018 Nov; 14(45):e1802417. PubMed ID: 30247806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
    Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
    Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.